BACE1 and Alzheimer disease: BACE1 has been proposed as a viable therapeutic target for AD; however, challenges with the currently investigated BACE1 inhibitors, involving low oral bioavailability, long serum half-life, and low blood–brain barrier (BBB) penetration ratio (Vassar, 2014), have not been fully overcome yet.